Evogene Expands AI Chemistry Platform; Six Collaborations and Leaner Cash Burn
Aug 18, 2026, 8:09 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The update signals meaningful progress (AI-accelerated platform, new collaborations, expanded molecule space) and a clearer cash runway, which can improve investor sentiment and reduce downside risk. However, continued net losses and near-term revenue catalysts remain uncertain, so upside depends on progression of collaborations and eventual monetization.
AI summary
What happened, with direct paths to the underlying reporting
Evogene reports progress on its 2025 transformation into an AI-driven computational chemistry leader for pharma and agriculture. The update highlights a 110-billion-molecule virtual space, autonomous AI Agents, and four new 2026 collaborations within six active programs. With cash burn guided down to $8.5–$9.5 million and Lavie Bio/Biomica exits, the company aims to extend its runway while pursuing revenue from partnerships.
Evogene advances its 2025 strategic pivot to AI-driven computational chemistry.
Six active collaborations; four new in 2026; two hit-ID milestones achieved.
2026 cash burn guided at $8.5–$9.5M; June 30 cash about $9.3M.
ChemPass AI expands virtual space to ~110B molecules with autonomous AI Agents.
Lavie Bio and Biomica exits; ICL asset sale boosts liquidity; Evogene dividends.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
